Why did EVE.SW stock fall intraday today?

EVE.SW stock fell **-6.02%** intraday to **CHF0.78** on 13 Jan 2026 amid heavier volume (14,166) and selling pressure. Technical weakness below the 50-day average and lack of near-term earnings or positive catalysts amplified the drop.

What are the main financial strengths for EVE.SW stock?

EvoNext has strong liquidity: **cash per share CHF0.87** and **current ratio 8.34**. Price-to-book **0.90** signals low market valuation versus book. These balance-sheet strengths reduce short-term solvency risk.

What price targets does Meyka provide for EVE.SW stock?

Meyka AI's forecast model projects **CHF0.82** (monthly), **CHF1.17** (quarterly) and **CHF3.13** (12 months). These imply upside of **5.13%**, **50.00%**, and **301.61%** from **CHF0.78**. Forecasts are model-based projections and not guarantees.

Is EVE.SW stock a buy for long-term investors?

EVE.SW stock may merit a HOLD for investors focused on balance-sheet strength but not yet a clear BUY. Meyka grades the stock **B (HOLD)** due to cash reserves but negative profitability and small market cap that limit conviction.

CH Stocks

EVE.SW stock -6.02% intraday at CHF0.78 on 13 Jan 2026: Watch cash per share

ByDanny Kontos January 13, 2026January 13, 2026

EVE.SW stock fell -6.02% intraday to CHF0.78 on 13 Jan 2026, making it one of the top losers on the SIX Switzerland healthcare list today. Trading volume is 14,166 shares, nearly 2.54x average volume, signalling short-term selling pressure. The move follows weak near-term momentum versus the 50-day average CHF0.84 and the 200-day average CHF1.02. We use Meyka AI as an AI-powered market analysis platform to frame liquidity, valuation and a short-term price outlook for EvoNext Holdings S.A. (EVE.SW) on the SIX.